Concerning sorafenib as monotherapy for HCC after liver resection, theoretically, it is worth investigating its adjuvant use to prevention of HCC recurrence for the reason that activation of the epidermal growth factor receptor, platelet-derived growth factor/receptor contributes to carcinogenesis, which is mediated by signaling pathways of angiogenesis and cell proliferation such as Ras/Raf/MEK/ERK [17]. The gene discussed is EGFR; the disease is hepatocellular carcinoma.